Gilead Looking Healthy for Takeover

Gilead Sciences remains an attractive takeover target for major drugmakers because of its promising pipeline and consistent revenue, primarily from HIV medicines Viread, Truvada and Atripla. However, a takeover of the biotech firm may prove difficult because Gilead’s growth strategy has always focused on “building a very strong independent company,” Chief Operating Officer John Milligan [...]